ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.055 AUD 1.85% Market Closed
Market Cap: 111.3m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

ImpediMed Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ImpediMed Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
ImpediMed Ltd
ASX:IPD
Free Cash Flow
-AU$20.9m
CAGR 3-Years
-10%
CAGR 5-Years
1%
CAGR 10-Years
-12%
R
Respiri Ltd
ASX:RSH
Free Cash Flow
-AU$6.6m
CAGR 3-Years
4%
CAGR 5-Years
-1%
CAGR 10-Years
3%
C
Cyclopharm Ltd
ASX:CYC
Free Cash Flow
-AU$13.1m
CAGR 3-Years
-24%
CAGR 5-Years
-65%
CAGR 10-Years
N/A
Cochlear Ltd
ASX:COH
Free Cash Flow
AU$299m
CAGR 3-Years
15%
CAGR 5-Years
11%
CAGR 10-Years
14%
Optiscan Imaging Ltd
ASX:OIL
Free Cash Flow
-AU$5.8m
CAGR 3-Years
-39%
CAGR 5-Years
-33%
CAGR 10-Years
-24%
EMvision Medical Devices Ltd
ASX:EMV
Free Cash Flow
-AU$6.3m
CAGR 3-Years
-11%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

ImpediMed Ltd
Glance View

Market Cap
111.3m AUD
Industry
Health Care

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

IPD Intrinsic Value
0.079 AUD
Undervaluation 30%
Intrinsic Value
Price

See Also

What is ImpediMed Ltd's Free Cash Flow?
Free Cash Flow
-20.9m AUD

Based on the financial report for Jun 30, 2024, ImpediMed Ltd's Free Cash Flow amounts to -20.9m AUD.

What is ImpediMed Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-12%

Over the last year, the Free Cash Flow growth was 13%. The average annual Free Cash Flow growth rates for ImpediMed Ltd have been -10% over the past three years , 1% over the past five years , and -12% over the past ten years .

Back to Top